An increasing proportion of patients achieve a low disease activity state or remission when switched from infliximab to abatacept regardless of initial infliximab treatment response: results from the ATTEST trial

0840

  • Schiff, M
  • Keiserman, M
  • Moniz-Reed, D
  • Le Bars, M
  • Becker, J C
  • Zhao, C
  • Dougados, M

  • 1University of Colorado, Denver, CO, United States

    2Pontificial Catholic Univ, Porto Alegre, Brazil

    3Bristol-Myers Squibb, Princeton, NJ, United States

    4Bristol-Myers Squibb, Rueil-Malmaison, France

    5Hospital Cochin, Descartes Univ, Paris, France

International Journal of Rheumatic Diseases 13:p 103, July 2010.
Copyright © 2010 John Wiley & Sons, Inc.
View full text|Download PDF